Woodline Partners LP Affimed N.V. Transaction History

Woodline Partners LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $238,351 - $403,738	121,608 Added 4.84%	2,631,691 $5.42 Million
Q2 2022 Aug 15, 2022	BUY	$2.27 - $4.86 $5.7 Million - $12.2 Million	2,510,083 New	2,510,083 $6.95 Million
Q3 2020 Nov 16, 2020	SELL	$3.26 - $4.73 $1.89 Million - $2.74 Million	-579,597 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$1.58 - $4.63 $169,944 - $498,002	107,560 Added 22.79%	579,597 $2.68 Million
Q1 2020 May 15, 2020	BUY	$1.44 - $3.02 $679,733 - $1.43 Million	472,037 New	472,037 $746,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.